trending Market Intelligence /marketintelligence/en/news-insights/trending/8oSVf89zqM0OD9xLcLgdXw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

BriaCell Therapeutics' board approves 1-for-300 reverse stock split

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

BriaCell Therapeutics' board approves 1-for-300 reverse stock split

BriaCell Therapeutics Corp. said its board approved a consolidation of its shares that was announced in October.

The company will undertake a reverse stock split of its shares at a ratio of 1-for-300, effective Jan. 2, 2020. The West Vancouver, Canada-based company expects to gain a listing on a recognized stock exchange in the U.S. through the reverse split.

BriaCell will reduce its issued and outstanding from 216,589,090 to approximately 721,924 after the split.

BriaCell is a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is currently listed on the TSX-V and the OTCQB.